This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

Americans elect their leaders on the premise that those individuals will be capable of making the right decisions on difficult, as well as easy, issues. An issue on which members of Congress might ...

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

UBS does not expect biopharma sector to outperform in 2025. Its analysts still see GLP-1 theme dominating the space next year ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...